Curis Inc (CRIS)
NASDAQ:CRIS
Want to see CRIS full AI Analyst Report?
CRIS Stock Chart & Stats
$0.60
-$0.29(-7.77%)
At close: 4:00 PM EST
$0.60
-$0.29(-7.77%)
Day’s Range― - ―
52-Week Range$0.38 - $2.48
Previous CloseN/A
Volume44.55K
Average Volume (3M)68.01K
Market Cap
$16.41M
Enterprise Value-$8.32M
Total Cash (Recent Filing)$15.00M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta3.09
Next Earnings
Jul 30, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding38,978,690
10 Day Avg. Volume74,344
30 Day Avg. Volume68,010
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)23.79
Price to Sales (P/S)13.76
P/FCF Ratio-4.78
Enterprise Value/Market Cap-0.51
Enterprise Value/Revenue-1.18
Enterprise Value/Gross Profit-1.18
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$11.00Price Target Upside1733.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.82
Revenue Forecast (FY)$7.55M
Bulls Say, Bears Say
Bulls Say
Registrational PCNSL Study ProgressAdvancing a registrational PCNSL study with an ORR endpoint and potential for accelerated submissions is a durable value driver: success could shorten regulatory timelines, create a clear path to approval in an ultra‑orphan indication, and materially change commercial prospects and partner interest.
Collaborations And Regulatory EngagementDeep scientific collaborations and active FDA/EMA engagement improve trial design, de‑risk regulatory pathways, and boost credibility with partners and payors. These durable relationships strengthen execution capability and raise the probability of efficient, approvable development programs over the next 2–6 months and beyond.
Expanded Capital-raising FlexibilityBroad shareholder approval to increase authorized shares provides lasting structural flexibility to raise equity when needed, enabling the company to manage financing for clinical programs. This governance backing reduces short‑term fundraising friction and supports execution of multi‑stage development plans.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow is a structural constraint: the company cannot self‑fund operations from internal cash, forcing recurring external financing. Over 2–6 months this elevates dilution risk, pressures strategic choices, and ties program continuity to successful capital raises or milestone receipts.
Small, Declining Revenue And Heavy LossesLow and falling collaboration revenue combined with outsized operating losses indicate the business remains far from break‑even. This structural mismatch limits reinvestment capacity, increases reliance on partners or financings, and makes multi‑period planning fragile absent near‑term clinical or financing successes.
Nasdaq Listing And Liquidity RiskA delisting determination is a durable governance and liquidity risk: loss of Nasdaq listing could reduce investor access, limit institutional participation, and increase financing costs. Over months this raises execution risk for trials and heightens urgency for non‑market funding or rapid operational milestones.
Curis News
CRIS FAQ
What was Curis Inc’s price range in the past 12 months?
Curis Inc lowest stock price was $0.38 and its highest was $2.48 in the past 12 months.
What is Curis Inc’s market cap?
Curis Inc’s market cap is $16.41M.
When is Curis Inc’s upcoming earnings report date?
Curis Inc’s upcoming earnings report date is Jul 30, 2026 which is in 39 days.
How were Curis Inc’s earnings last quarter?
Curis Inc released its earnings results on May 12, 2026. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$0.327 by -$0.923.
Is Curis Inc overvalued?
According to Wall Street analysts Curis Inc’s price is currently Undervalued.
Does Curis Inc pay dividends?
Curis Inc does not currently pay dividends.
What is Curis Inc’s EPS estimate?
Curis Inc’s EPS estimate is -0.41.
How many shares outstanding does Curis Inc have?
Curis Inc has 38,978,690 shares outstanding.
What happened to Curis Inc’s price movement after its last earnings report?
Curis Inc reported an EPS of -$1.25 in its last earnings report, missing expectations of -$0.327. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Curis Inc?
Currently, no hedge funds are holding shares in CRIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Curis Inc
Curis, Inc. is a biotechnology firm dedicated to identifying and advancing therapeutic compounds for various human cancers across the United States. Its current clinical-stage pipeline features Emavusertib, an oral small molecule presently in Phase 1/2 trials for treating non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. Another significant candidate is CI-8993, a monoclonal antibody designed to counteract the V-domain Ig suppressor of T cell activation. The company's broader development initiatives also encompass Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes, being developed for patients with MYC-altered diffuse large B-cell lymphoma. Additional candidates include CA-170, an oral small molecule aimed at advanced solid tumors and lymphomas, and CA-327, an oncology drug in its pre-investigational new drug phase. Curis has established key collaborative agreements, notably with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the co-development and marketing of Erivedge, an orally administered small molecule that inhibits the hedgehog signaling pathway for advanced basal cell carcinoma. Furthermore, it partners with Aurigene Discovery Technologies Limited on the research, development, and commercialization of small molecule compounds within the immuno-oncology and precision oncology sectors. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
CRIS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress and clear near‑term milestones — notably advancement of a registrational PCNSL study with the potential for accelerated submissions, initiation and early milestones for a CLL proof‑of‑concept study, encouraging early collaborator data in gastroesophageal cancer, and collaborative/regulatory engagement. Offsetting these positives are a sizable increase in reported net loss (driven by warrant fair‑value changes), higher G&A tied to financing, a cash runway that depends in part on a milestone contingent warrant exercise, and expected enrollment variability in ultra‑orphan indications. On balance, the clinical and regulatory momentum and near‑term data/milestone visibility materially outweigh the financial and enrollment risks described.View all CRIS earnings summariesCRIS Stock 12 Month Forecast
Average Price Target
$11.00
▲(1733.33% Upside)
Technical Analysis
Ownership Overview
1.02% Insiders
1.20% Mutual Funds
36.28% Other Institutional Investors
60.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---